Literature DB >> 9766750

c-myc locus amplification and the acquisition of trisomy 8 in the evolution of chronic myeloid leukaemia.

B A Jennings1, K I Mills.   

Abstract

The biological progression of chronic myeloid leukaemia is often associated with secondary cytogenetic abnormalities but the molecular mechanisms underlying this progression are poorly understood. This study explores the association of c-myc gene amplification with the progression of chronic myeloid leukaemia in fourteen individuals. Three of these cases showed amplification of c-myc during the course of their disease. Cytogenetic and molecular analysis of serial samples from some patients suggested the successive expansion of distinct clones of malignant cells. Our findings also suggest that trisomy 8 and locus amplification could represent alternative mechanisms for increasing c-myc gene dosage.

Entities:  

Mesh:

Year:  1998        PMID: 9766750     DOI: 10.1016/s0145-2126(98)00097-6

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  10 in total

1.  The Myc target gene JPO1/CDCA7 is frequently overexpressed in human tumors and has limited transforming activity in vivo.

Authors:  Rebecca C Osthus; Baktiar Karim; Julia E Prescott; B Douglas Smith; Michael McDevitt; David L Huso; Chi V Dang
Journal:  Cancer Res       Date:  2005-07-01       Impact factor: 12.701

Review 2.  Molecular and cellular bases of chronic myeloid leukemia.

Authors:  Yaoyu Chen; Cong Peng; Dongguang Li; Shaoguang Li
Journal:  Protein Cell       Date:  2010-02-06       Impact factor: 14.870

Review 3.  Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia.

Authors:  Elias J Jabbour; Timothy P Hughes; Jorge E Cortés; Hagop M Kantarjian; Andreas Hochhaus
Journal:  Leuk Lymphoma       Date:  2013-11-12

Review 4.  The aneuploidy paradox: costs and benefits of an incorrect karyotype.

Authors:  Jason M Sheltzer; Angelika Amon
Journal:  Trends Genet       Date:  2011-08-26       Impact factor: 11.639

5.  A case of acute myeloid leukemia-M2 with trisomy 4 in addition to t(8;21).

Authors:  P J Trivedi; P S Patel; M M Brahmbhatt; B P Patel; S B Gajjar; R R Iyer; E H Parikh; S N Shukla; P M Shah; S R Bakshi
Journal:  Indian J Hum Genet       Date:  2008-01

Review 6.  Chronic Myeloid Leukemia: Beyond BCR-ABL1.

Authors:  Ting Zhou; L Jeffrey Medeiros; Shimin Hu
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

7.  Amplification of c-MYC and MLL Genes as a Marker of Clonal Cell Progression in Patients with Myeloid Malignancy and Trisomy of Chromosomes 8 or 11.

Authors:  S Angelova; M Jordanova; B Spassov; V Shivarov; M Simeonova; I Christov; P Angelova; K Alexandrova; A Stoimenov; V Nikolova; I Dimova; P Ganeva; N Tzvetkov; E Hadjiev; S Toshkov
Journal:  Balkan J Med Genet       Date:  2011-12       Impact factor: 0.519

8.  Trisomy 8 in leukemia: A GCRI experience.

Authors:  Sonal R Bakshi; Manisha M Brahmbhatt; Pina J Trivedi; Esha N Dalal; Dharmesh M Patel; Sejal S Purani; Shilin N Shukla; Pankaj M Shah; Prabhudas S Patel
Journal:  Indian J Hum Genet       Date:  2012-01

9.  On the Power of Additional and Complex Chromosomal Aberrations in CML.

Authors:  Karin M Greulich-Bode; Barbara Heinze
Journal:  Curr Genomics       Date:  2012-09       Impact factor: 2.236

Review 10.  Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia.

Authors:  Yaoyu Chen; Shaoguang Li
Journal:  Onco Targets Ther       Date:  2014-01-31       Impact factor: 4.147

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.